Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05143996 · ClinicalTrials.gov registry record · Phase 1
CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML), sponsored by Cullinan Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 11
- Study locations
NCT05143996: Recruiting Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML), sponsored by Cullinan Therapeutics.
NCT05143996 is a Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML) that is actively recruiting participants, run by Cullinan Therapeutics. The registered enrollment target is 60 participants, below the 83-participant average among 19 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (28% lower). The trial reports 11 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05143996, a Phase 1 study of Myelodysplastic Syndrome (MDS) and Relapsed/Refractory Acute Myeloid Leukemia (AML), is actively recruiting participants, sponsored by Cullinan Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 11
- Study locations
Study Summary
CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Primary Outcome
TEAEs will be defined as adverse events that are reported for the first time following study drug administration for worsening of a pre-existing event after the first dose
Conditions Studied
Interventions
- DRUG CLN-049
Study Locations (11)
Florida
- University of Miami Health System - Miami
- Moffitt Cancer Center - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
- New York University - New York
Alabama
- University of Alabama O'Neal Cancer Center - Birmingham
California
- UCLA - Los Angeles
Georgia
- Emory University Hospital - Atlanta
Massachusetts
- Massachusetts General Hospital - Boston
North Carolina
- Duke Cancer Center - Durham
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2021-11-18 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
What NCT05143996 shows while recruiting
NCT05143996 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 83-participant average among 19 other Myelodysplastic Syndrome (MDS) trials with a reported enrollment target (28% lower).
The record links to 2 conditions, with Myelodysplastic Syndrome (MDS) appearing as the primary indexed condition, and to 1 intervention - of which CLN-049 is the first listed.
NCT05143996 lists 11 locations in 9 states (Florida, New York, Alabama).
Frequently Asked Questions
What is clinical trial NCT05143996 about?
NCT05143996 is a clinical study titled "CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)". CLN-049-001 is a Phase 1, open-label, multicenter, first-in-human trial of CLN-049 in patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
What is the current status of trial NCT05143996?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2021-11-18. Estimated completion is 2027-06.
What conditions does trial NCT05143996 study?
This clinical trial studies the following conditions: Myelodysplastic Syndrome (MDS), Relapsed/Refractory Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT05143996?
The interventions under investigation include: CLN-049 (DRUG).
Who is sponsoring clinical trial NCT05143996?
This trial is sponsored by Cullinan Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05143996 being conducted?
This trial has 11 study locations across Alabama, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelodysplastic Syndrome (MDS)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05143996's enrollment target sits among peer trials
60 7th of 19 higher than 13 of 19 other Myelodysplastic Syndrome (MDS) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelodysplastic Syndrome (MDS) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
RECRUITING · Phase 1
-
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
RECRUITING · Phase 1
-
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
RECRUITING · Phase 1
-
CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant
ACTIVE NOT RECRUITING · Phase 1
-
Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN
ACTIVE NOT RECRUITING · Phase 1
-
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI